Iterum Announces Positive Topline Results from Phase 3 Trial of Oral Sulopenem
The Dublin-based biotech is designing another phase 3 trial for the oral treatment in patients with uncomplicated urinary tract infections, Iterum said Tuesday night. More clarity on the trial design could come as early as third-quarter earnings, RBC Capital Markets analysts estimated in a note to clients.